APA (7th ed.) Citation

Peyrin-Biroulet, L., Chapman, J. C., Colombel, J., Caprioli, F., D'Haens, G., Ferrante, M., . . . Duan, W. R. (2024). Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. New England Journal of Medicine, 391(3), 213. https://doi.org/10.1056/NEJMoa2314585

Chicago Style (17th ed.) Citation

Peyrin-Biroulet, L., et al. "Risankizumab Versus Ustekinumab for Moderate-to-Severe Crohn's Disease." New England Journal of Medicine 391, no. 3 (2024): 213. https://doi.org/10.1056/NEJMoa2314585.

MLA (9th ed.) Citation

Peyrin-Biroulet, L., et al. "Risankizumab Versus Ustekinumab for Moderate-to-Severe Crohn's Disease." New England Journal of Medicine, vol. 391, no. 3, 2024, p. 213, https://doi.org/10.1056/NEJMoa2314585.